Founded in 1841 and listed on First North Stockholm, Stille is well-known in the premium instrument segment for its product leadership, outstanding quality, and durability, with focus on high-precision cardio and plastic procedures (2000+ SKUs). This, while being a clear market and innovation leader in the attractive and protected niche market for mobile c-arm tables specifically designed for minimally invasive cardiovascular procedures. Stille is today headquartered in Torshälla, Sweden (HQ and production), with offices in Switzerland (sales and production) and in the US (sales and assembly), the company is active in 70+ markets with 50+ distributors globally.

Stille facts



Impilo entry date

January 2024


Eskilstuna, Sweden

Management team

Torbjörn Sköld (CEO), Niklas Carlén (CFO)

Impilo team

Victor Steien
Fredrik Strömholm
Frederikke Beck
Paula Johansson

No of employees


Revenue development, SEKm


PF EBITDA development, SEKm


Investment Thesis

  • Sizeable addressable market and growing at 6-7% p.a. in sticky niches for premium surgical instruments
  • Stille is well positioned to continue outgrowing the market, leveraging its over-exposure to faster growing segments (cardio and surgery), its strong brand, value proposition, and distribution network
  • Scope to drive profitable growth through increased direct sales efforts in selected key markets / repatriate distributor margins and through continued streamlining and automation of resource intensive steps of the production process
  • Fehling Instruments comes with a highly complementary product offering, enlarged commercial infrastructure paving the way for cross-selling opportunities, and a strengthened R&D function for the instruments business

UN SDG Goals